At the end of 2022, the acquisition of the German company Altamedics represented the first step in consolidating Abiogen’s direct presence in the international panorama. A few months later, the acquisition of the Swiss company, Effrx, allows Abiogen Pharma to bring back effervescent sodium alendronate, a key molecule in the treatment of osteoporosis.
The history of Altamedics began in 2009, in Cologne.
The company is strictly focused on the distribution of niche hospital medicines and has over time become a point of reference for the German hospital market.
After the acquisition at the end of 2022, Abiogen’s goal is to find synergies in the portfolios and penetrate the German market with its core products/assets.
Visit the Altamedics website to find out more: https://www.altamedics.de/
Effrx was founded in 2010 in Freienbach, Switzerland. The company is focused on developing and commercializing drugs, particularly for musculoskeletal and rare diseases. With a lean and flexible business model, the company is active in 29 countries and aims to further expand its range of action
Visit the Effrx website to find out more: https://www.effrx.com/